Scholarlink

Objective <p>This study investigated whether first-trimester serum levels of adiponectin, leptin, resistin, and visfatin can predict the development of preeclampsia in pregnant women.</p> Methods <p>A prospective case-enriched case–control study was conducted with 199 pregnant women recruited during their first trimester (11–13&#xa0;weeks of gestation). Participants were followed longitudinally, and recruitment was continued until a sufficient number of women who subsequently developed preeclampsia were identified. Thus, the final analytic cohort was intentionally enriched for PE outcomes and does not reflect population-based disease prevalence.</p> Results <p>Early-pregnancy adiposity indices, including ultrasound-derived visceral and subcutaneous fat thickness, were also assessed given their emerging role as metabolic and inflammatory risk factors for preeclampsia. Adiponectin was lower in the PE group (9.57 ± 2.88 vs. 10.13 ± 3.16&#xa0;ng/mL, <i>p</i> = 0.031). In unadjusted comparisons, mean leptin was marginally lower among women who developed PE (19.52 ± 4.11 vs. 20.29 ± 5.01&#xa0;ng/mL, <i>p</i> = 0.013). However, in multivariate logistic regression controlling for age, BMI, and parity, leptin was positively associated with PE (OR = 1.18, 95% CI 1.04–1.34, <i>p</i> = 0.012), indicating that after adjusting for covariates, higher leptin levels predicted an increased PE risk. Resistin and visfatin did not show large unadjusted mean differences, though resistin was significant in adjusted models (OR = 1.35, <i>p</i> = 0.004).</p> Conclusions <p>First-trimester adipocytokines demonstrate significant predictive capability for the development of preeclampsia, with resistin showing superior diagnostic performance. The combination of multiple biomarkers enhances predictive accuracy beyond individual markers. These findings support the potential integration of adipocytokine assessment into early pregnancy screening protocols, pending validation in diverse populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First-trimester adipocytokine levels as predictive biomarkers for preeclampsia: a prospective case-control study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Nuzhat Parveen,
  • Naveed Iqbal,
  • Abdelrahim Awadelkarim Abdelrahman Mohamed,
  • Syed Monowar Alam Shahid,
  • Rania Abdeen Hussain Abdalla,
  • Gamal Eldin Mohamed Osman Elhussein,
  • Mohd. Saleem,
  • Afreen Arshad Choudhry,
  • Mohd Shahid Khan

摘要

Objective

This study investigated whether first-trimester serum levels of adiponectin, leptin, resistin, and visfatin can predict the development of preeclampsia in pregnant women.

Methods

A prospective case-enriched case–control study was conducted with 199 pregnant women recruited during their first trimester (11–13 weeks of gestation). Participants were followed longitudinally, and recruitment was continued until a sufficient number of women who subsequently developed preeclampsia were identified. Thus, the final analytic cohort was intentionally enriched for PE outcomes and does not reflect population-based disease prevalence.

Results

Early-pregnancy adiposity indices, including ultrasound-derived visceral and subcutaneous fat thickness, were also assessed given their emerging role as metabolic and inflammatory risk factors for preeclampsia. Adiponectin was lower in the PE group (9.57 ± 2.88 vs. 10.13 ± 3.16 ng/mL, p = 0.031). In unadjusted comparisons, mean leptin was marginally lower among women who developed PE (19.52 ± 4.11 vs. 20.29 ± 5.01 ng/mL, p = 0.013). However, in multivariate logistic regression controlling for age, BMI, and parity, leptin was positively associated with PE (OR = 1.18, 95% CI 1.04–1.34, p = 0.012), indicating that after adjusting for covariates, higher leptin levels predicted an increased PE risk. Resistin and visfatin did not show large unadjusted mean differences, though resistin was significant in adjusted models (OR = 1.35, p = 0.004).

Conclusions

First-trimester adipocytokines demonstrate significant predictive capability for the development of preeclampsia, with resistin showing superior diagnostic performance. The combination of multiple biomarkers enhances predictive accuracy beyond individual markers. These findings support the potential integration of adipocytokine assessment into early pregnancy screening protocols, pending validation in diverse populations.